Thermo Fisher Live Event Shorts

31. Major Advancements In mRNA 1/29/2024

    Experts on this Cell & Gene live event discuss the major scientific biological advances in understanding the potential for mRNA-based immunotherapies vaccines for cancer over the last 2 years.

32. Genentech, Myeloid's Approaches To mRNA Technologies 1/29/2024

    Experts at a Cell & Gene Live event discussed the use of mRNA technology in cancer immunotherapy, including a brief overview of the different approaches being used to leverage mRNA technology.

33. Scaling Viral Vectors 11/13/2023

    Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.

34. Overcoming Capacity Constraints 11/13/2023

    How can CGT biotechs overcome issues such as building an in house facility and ultimately get their therapies to patients.

35. Market Demand For AAV Vectors 11/13/2023

    Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.

36. Regulatory Compliance And Viral Vectors 11/13/2023

    Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.

37. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

38. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

39. Driving Down COGS Audience Q&A 8/18/2023

    Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.

40. Safety And Efficiency Of Source Material Collection 8/18/2023

    Expert CTO's detail how automation improves safety and efficiency when collecting source material.